Research Papers:

DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1

Jogitha Selvarajah, Androulla Elia, Veronica A. Carroll _ and Abdeladim Moumen

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2015; 6:427-440. https://doi.org/10.18632/oncotarget.2813

Metrics: PDF 3013 views  |   HTML 4167 views  |   ?  


Jogitha Selvarajah1, Androulla Elia1, Veronica A. Carroll1,* and Abdeladim Moumen2,*

1 Cardiovascular and Cell Sciences Research Institute, St George’s University of London, Cranmer Terrace, UK

2 Division of Medical Biotechnology, MAscIR Institution, Rabat, Morocco

* These authors contributed equally to this work


Veronica A. Carroll, email:

Abdeladim Moumen, email:

Keywords: mTORC1, mTORC2, Chk1, DNA damage response, cell cycle arrest, breast cancer

Received: October 16, 2014 Accepted: November 14, 2014 Published: November 15, 2014


mTOR signalling is commonly dysregulated in cancer. Concordantly, mTOR inhibitors have demonstrated efficacy in a subset of tumors and are in clinical trials as combination therapies. Although mTOR is associated with promoting cell survival after DNA damage, the exact mechanisms are not well understood. Moreover, since mTOR exists as two complexes, mTORC1 and mTORC2, the role of mTORC2 in cancer and in the DNA damage response is less well explored. Here, we report that mTOR protein levels and kinase activity are transiently increased by DNA damage in an ATM and ATR-dependent manner. We show that inactivation of mTOR with siRNA or pharmacological inhibition of mTORC1/2 kinase prevents etoposide-induced S and G2/M cell cycle arrest. Further results show that Chk1, a key regulator of the cell cycle arrest, is important for this since ablation of mTOR prevents DNA damage-induced Chk1 phosphorylation and decreases Chk1 protein production. Furthermore, mTORC2 was essential and mTORC1 dispensable, for this role. Importantly, we show that mTORC1/2 inhibition sensitizes breast cancer cells to chemotherapy. Taken together, these results suggest that breast cancer cells may rely on mTORC2-Chk1 pathway for survival and provide evidence that mTOR kinase inhibitors may overcome resistance to DNA-damage based therapies in breast cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 2813